To investigate the clinical relevance of FOXA2 expression in renal cell carcinoma, we examined FOXA2 expression in renal tissue microarray (TMA) specimens from a cohort of 75 patients with RCC by immunohistochemistry using a specific anti-FOXA2 antibody (Fig. S1A). Here, FOXA2 is linked to renal cell carcinoma.